Latest Diabetic retinopathy Stories
SOUTHAMPTON, England, August 20, 2014 /PRNewswire/ -- Phase I Trial of Plasma Kallikrein Inhibitor to be Conducted in the US KalVista Pharmaceuticals ("KalVista"),
TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
DME is the third approved indication for EYLEA in the U.S. TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., July 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment
UITHOORN, The Netherlands, July 14, 2014 /PRNewswire/ -- - HOYA signs a multiple-year contract with Eye diagnostics innovator i-Optics to offer opticians the EasyScan 3
TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
ATLANTA, June 23, 2014 /PRNewswire/ -- Alimera Sciences, Inc.
GAITHERSBURG, Md., June 16, 2014 /PRNewswire/ -- The 74th Scientific Session of the American Diabetes Association (ADA) was the setting that released the initial results from the recently completed
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.